



Contents

1	Dataset construction and storage	2
2	Import and Data Structure	2
3	Data Validation and Integrity Check	2
4	Technical Filtering	3
5	Filtering of Invariant CpGs	3
6	Correction of Infinium I/II Probe Bias	4
7	Transformation to M-values	4
8	Batch-Effect Correction	4
9	Preliminary Statistical Filters	4
10	Correlation Pruning	4
11	Feature Standardization for Machine Learning	4
A	Filtering lists	5
A.1	Reducing the risk of false discovery enabling identification of biologically significant genome-wide methylation status using the humanmethylation450 array	5
A.2	Discovery of cross-reactive probes and polymorphic cgps in the illumina infinium humanmethylation450 microarray	5
A.3	Critical evaluation of the Illumina MethylationEPIC BeadChip microarray for whole-genome DNA methylation profiling	5
A.4	Comprehensive characterization, annotation and innovative use of infinium dna methylation beadchip probes	6
A.5	Identification of polymorphic and off-target probe binding sites on the Illumina Infinium MethylationEPIC BeadChip	6
A.6	Comparative Overview	6

Abstract

MANCA L'ABSTRACT, LO SCRIVO DOPO.
AGGIUNGI I LINK AI NOTEBOOK - GITHUB SIA PER DATASET CONSTRUCTION AND STORAGE CHE PER IL DATASET PRE PROCESSING.

1 Dataset construction and storage

I constructed the working methylation matrix in three stages, prioritizing speed, low memory usage, and reproducible I/O.

1. **Ingestion and transposition.** I parsed the GEO Series Matrix for GSE69914, skipping the 73-line metadata header. The source table is organized as $CpG \times sample$ with ID_REF as CpG identifiers; I coerced all sample columns to numeric (invalid entries set to NaN) and then transposed the matrix to the analysis layout $sample \times CpG$. After transposition, I promoted the original column names (GSM accessions / basenames) to a dedicated identifier column named `id_tissue` and kept CpG probe columns only (prefix `cg` or `ch`).
2. **Label derivation and append-only write.** I derived the class label directly from GSM metadata by parsing the field `status` ($0=normal$, $1=normal-adjacent$, $2=breast\ cancer$, $3=normal-BRCA1$, $4=cancer-BRCA1$), producing a numeric `label` in $\{0, 1, 2, 3, 4\}$. To avoid an in-memory join on a very wide table ($\sim 485k$ CpGs), I streamed through the transposed file once and appended `label` row-wise, preserving row order and ensuring constant memory usage.
3. **Columnar storage and typed schema.** For long-term access, I wrote the labeled table to columnar Parquet with a fixed schema: `label` as `Int8` and probe intensities as `Float32`. I applied a lazy, regex-based column projection (`cg | ch`) to cast all probe columns in one pass and compressed the file with lossless LZ4. This yields fast full-table reads and efficient column projection (both in Polars and pandas) without repeatedly parsing large CSV text.

This procedure produces a compact, typed matrix that enables rapid downstream preprocessing (technical filtering, normalization) and modeling without incurring large RAM overhead or costly re-ingestion steps.

2 Import and Data Structure

The processed dataset is imported from the LZ4-compressed `.parquet` file generated in the previous step. The structure is already optimized for analysis.

- **File format:** columnar Parquet (LZ4 compression) for fast I/O.
- **Rows:** samples (one per tissue).
- **Columns:**
 - `id_tissue`: unique sample identifier.
 - `label`: numeric class code (`Int8`).
 - `cg`, `ch`: methylation probes (`Float32`).
- **Import method:** read via `Polars` (or `pandas`) with column projection for efficient partial loading.

Precision and data representation. Because β -values are strictly bounded within $[0, 1]$ [1], and methylation differences of biological interest typically occur at magnitudes between 10^{-2} and 10^{-3} , single-precision floating point (`float32`, machine $\epsilon \approx 10^{-7}$) provides more than adequate numerical accuracy while significantly reducing memory usage and I/O time. This representation is further supported by recent large-scale genomics frameworks that process molecular features, including DNA methylation data, entirely in `float32` precision [2].

Moreover, this format ensures minimal memory usage and extremely fast access for all downstream preprocessing and analysis tasks.

3 Data Validation and Integrity Check

Data Validation. I validated the structural integrity of the processed dataset to ensure that its layout, types, and values were correctly preserved after conversion and compression.

- **Dimensions:** the dataset contains $(407, 485.514)$ entries, corresponding to **samples** \times **CpG loci**. ✓ confirmed as expected: **407 samples and 485.514 probes**.
- **Data types:** `id_tissue` is stored as `String`, `label` as `Int8`, and probe intensities as `Float32`, ensuring **compact representation** and sufficient precision for β -values. ✓ verified: `String`, `Int8`, `Float32` schema detected.
- **Value range:** all β -values fall within the valid range $0 \leq \beta \leq 1$, confirming their correct interpretation as methylation proportions. ✓ The observed range was $[0.000000, 0.997110]$.

Missing Value Analysis. Next, I performed a comprehensive check for missing values (NaN), as these can severely impact model performance and must be addressed before training.

- No missing entries (NaN) were detected across any CpG probe. ✓ Total NaN count: 0 — Overall missing rate: 0%.
- The methylation matrix is therefore **complete**, requiring **no filtering or imputation** procedures. ✓ Dataset confirmed **fully complete**.
- For future datasets:
 - If the overall missing rate is < 1%, imputation may be considered as an optional step.
 - If probe missingness exceeds 5% or sample missingness exceeds 10%, the affected entities should be discarded, following standard preprocessing practices [3].

This validation confirms the dataset is structurally sound, numerically consistent, and complete, enabling unbiased downstream variance modeling, differential methylation testing, and batch correction without any further cleaning

4 Technical Filtering

Technical filtering aims to remove unreliable or biologically confounded probes before normalization and statistical modeling. This step reduces noise, improves downstream reproducibility, and ensures that only high-confidence CpG loci are retained for analysis.

Exclusion of technical probe sets. Next, I removed probes listed in curated exclusion sets that are known to produce biased or ambiguous signals:

- **SNP-affected probes:** excluded to avoid spurious methylation differences caused by underlying genetic polymorphisms.
- **Cross-reactive probes:** removed according to validated lists from Naeem et al. (2014) [4] and Pidsley et al. (2016) [5], which identify probes that hybridize to multiple genomic loci.
- **Sex chromosome probes:** optionally filtered if downstream analyses focus exclusively on autosomal loci.

[**Results pending:** number of probes removed by each list, remaining CpG count, updated dataset size.]

Detection *p*-value filtering. For each probe, the detection *p*-value measures the probability that its fluorescence intensity is indistinguishable from the background. Probes with detection *p*-value > 0.01–0.05 in more than 1–5% of samples were excluded, as they likely represent unreliable hybridization or poor signal quality [6]. This filtering step follows Illumina’s quality control recommendations and standard practices for methylation array preprocessing.

[**Results pending:** summary of removed probes, percentage excluded, post-filter matrix dimensions.]

Annotation-based filtering. Finally, I performed a cross-check with official Illumina annotation files and updated curated probe databases [3] to ensure that only valid, well-characterized loci were retained. This step allows harmonization between older 450K annotations and updated genome builds (e.g., hg19 → hg38) and ensures consistent CpG naming across datasets.

[**Results pending:** number of probes retained after annotation matching, summary table or plot of final coverage.]

Outcome. After technical filtering, the dataset is expected to retain only high-confidence probes suitable for reliable normalization and subsequent biological interpretation.

[**Results pending:** summary of total retained CpGs, fraction of genome covered, histogram or density plot of detection *p*-values.]

5 Filtering of Invariant CpGs

Remove CpGs with very low variance (e.g., variance < 1×10^{-4}), as they carry no discriminative information (Naeem et al., 2014).

6 Correction of Infinium I/II Probe Bias

Integrate probe design information (Type I / Type II) from Illumina annotation files and inspect density distributions. Apply **Peak-Based Correction (PBC)** when clear bimodal peaks (near 0 and 1) are visible (Teschendorff et al., 2013). In parallel, apply **BMIQ normalization** as a robust alternative and compare results across normalization strategies.

7 Transformation to M-values

Convert β -values to M-values using $M = \log_2 \left(\frac{\beta}{1-\beta} \right)$ to stabilize variance and improve suitability for linear modeling (Du et al., 2010).

CpG Variability Diagnosis (post M-value):

Compute variance or interquartile range (IQR) across samples for each CpG to obtain a diagnostic ranking of variable loci. Highly variable CpGs are typically more informative for distinguishing normal and normal-adjacent tissues. (Naeem et al., 2014; Phipson et al., 2014). Optionally, visualize the variance distribution or perform PCA on top-variable CpGs to assess early group separation.

8 Batch-Effect Correction

Remove inter-array technical variation using **ComBat** (Johnson et al., 2007) or its methylation-specific extension **ComBat-met** (Wang et al., 2025).

If batch effects are confounded with biological groups, include the batch variable as a covariate in linear modeling (e.g., *limma*).

9 Preliminary Statistical Filters

Levene / Brown–Forsythe test: assesses homogeneity of variances across groups.

DiffVar: empirical Bayes model for differential variance detection (Phipson et al., 2014).

limma: moderated linear model for differential methylation, suitable for M-values and inclusion of covariates (Ritchie et al., 2015).

iEVORA: extension of EVORA for identifying CpGs with increased epigenetic instability in pre-neoplastic or field-defect tissues (Teschendorff et al., 2012).

10 Correlation Pruning

Remove redundant CpGs with high inter-correlation (e.g., Pearson $|r| > 0.9$) within local genomic regions to reduce collinearity (Gatev et al., 2020; Bommert et al., 2022).

11 Feature Standardization for Machine Learning

Standardize features (e.g., z-score transformation or **StandardScaler**) on M-values to ensure comparable scales across CpGs. Fit the scaler on the training fold and apply it to the test fold to prevent data leakage. (Friedman et al., 2010; Aref-Eshghi et al., 2025).

A Filtering lists

This appendix details the major technical filtering lists and annotations applied in Illumina 450K and EPIC methylation arrays to remove unreliable or ambiguous CpG probes.

A.1 Reducing the risk of false discovery enabling identification of biologically significant genome-wide methylation status using the humanmethylation450 array

Naeem *et al.* [7] proposed a structured filtering framework to reduce false discoveries by sequentially discarding probes based on hybridisation specificity and genomic integrity (Figure 1). The main exclusion steps are:

- Multi-mapping or cross-hybridising probes \Rightarrow *discard*.
- Probes overlapping repetitive elements (LINE/SINE/ALU) \Rightarrow *discard*.
- Probes targeting regions with INDELs \Rightarrow *discard*.
- Probes overlapping SNPs:
 - SNP at CpG or extension site \Rightarrow *discard*.
 - SNP near target but not interfering in bisulfite space \Rightarrow *keep*.

The resulting “discard” set therefore removes probes affected by cross-reactivity, structural polymorphisms (INDELs), and SNPs that alter CpG interrogation.

A.2 Discovery of cross-reactive probes and polymorphic cpgs in the illumina infinium humanmethylation450 microarray

Chen *et al.* [8] empirically identified probes in the 450K array that exhibit off-target hybridisation or overlap with common SNPs. For this project, only the **cross-reactive list** is available and used. This list enumerates $\sim 29k$ multi-mapping probes whose methylation signal cannot be uniquely attributed to one genomic locus.

A.3 Critical evaluation of the Illumina MethylationEPIC BeadChip microarray for whole-genome DNA methylation profiling

Pidsley *et al.* [9] provide a platform-level assessment of the EPIC array, with explicit *annotated probe lists* that flag probes whose methylation signal may be confounded by design- or genome-related artefacts. The focus is on probe categories and positions where technical bias arises, rather than on a universal, prescriptive blacklist. In particular, they catalogue:

- **Cross-hybridising CpG-targeting probes:** CpG probes showing sequence homology (off-target matches) to additional genomic loci, yielding non-unique hybridisation and potentially inflated or ambiguous β signals.
- **Cross-hybridising non-CpG-targeting probes:** off-target issues among CNG/non-CpG probes; these are typically excluded in CpG-centric analyses due to limited interpretability and higher risk of artefacts.
- **Probes overlapping common genetic variation:** annotation of variants from population data at three critical positions:
 - *At the interrogated CpG* (polymorphic CpG) — directly affects the presence of the CpG dinucleotide and the measured methylation state;
 - *At the single-base extension (SBE) site* (Type I) — perturbs extension and dye chemistry, biasing intensity ratios;
 - *Within the probe body* — can reduce binding affinity or alter hybridisation kinetics, especially for common variants.




Figure 1: Workflow for determining affected Probes.

A.4 Comprehensive characterization, annotation and innovative use of infinum dna methylation beadchip probes

Zhou *et al.* [10] released a unified probe annotation for both 450K and EPIC arrays with multiple binary mask columns (MASK_*) . Each mask flags probes to be removed due to specific technical artifacts:

- MASK_mapping: cross-hybridisation or ambiguous alignment;
- MASK.snp5: SNP within ± 5 bp of the CpG;
- MASK_extBase: SNP at the single-base extension;
- MASK_commonSNPs: overlap with common polymorphisms;
- MASK_nonCG: non-CpG-targeting probes;
- MASK_chrXY: probes located on X or Y chromosomes (optional).

This resource provides a programmatic and reproducible way to perform fine-grained probe masking.

A.5 Identification of polymorphic and off-target probe binding sites on the Illumina Infinium MethylationEPIC BeadChip

For the MethylationEPIC array, McCartney *et al.* [11] assessed probe design artifacts and published supplementary tables that include:

- cross-hybridising CpG-targeting probes;
- cross-hybridising non-CpG-targeting probes.

A.6 Comparative Overview

Table 1: Technical categories covered by each filtering resource.

Category	Naeem14	Chen13	Pidsley16	Zhou16	McCartney16
Cross-hybridisation / multi-mapping	Yes (Steps 1–2)	Yes	Yes	MASK_mapping	Table 2+3
SNP at CpG / extension base	Yes (Step 5)	–	Yes	MASK.snp5, MASK_extBase	–
Nearby SNP tolerated	Conditional (Step 6)	–	–	–	–
INDEL / structural variant	Yes (Step 3)	–	–	–	–
Non-CpG probes	–	–	Yes	MASK_nonCG	Table 3
Sex-chromosome probes (X/Y)	Yes	Yes	Yes	MASK_chrXY	–

References

- [1] L. Weinhold, S. Wahl, S. Pechlivanis, P. Hoffmann, and M. Schmid, “A statistical model for the analysis of beta values in dna methylation studies,” *BMC Bioinformatics*, vol. 17, no. 1, p. 480, 2016. DOI: [10.1186/s12859-016-1347-4](https://doi.org/10.1186/s12859-016-1347-4) [Online]. Available: <https://bmcbioinformatics.biomedcentral.com/articles/10.1186/s12859-016-1347-4>
- [2] B. P. de Almeida, G. Richard, H. Dalla-Torre, C. Blum, L. Hexemer, P. Pandey, S. Laurent, M. Lopez, A. Laterre, M. Lang, and et al., “A multimodal conversational agent for dna, rna and protein tasks,” *Nature Machine Intelligence*, 2025. DOI: [10.1038/s42256-025-01047-1](https://doi.org/10.1038/s42256-025-01047-1) [Online]. Available: <https://www.nature.com/articles/s42256-025-01047-1>
- [3] W. Zhou, P. W. Laird, and H. Shen, “Comprehensive characterization, annotation and innovative use of Infinium DNA methylation BeadChip probes,” *Nucleic Acids Research*, vol. 45, no. 4, e22, 2016. DOI: [10.1093/nar/gkw967](https://doi.org/10.1093/nar/gkw967) [Online]. Available: <https://academic.oup.com/nar/article/45/4/e22/2290937>
- [4] H. Naeem, N. C. Wong, Z. Chatterton, M. K. Hong, J. S. Pedersen, N. M. Corcoran, C. M. Hovens, and G. Macintyre, “Reducing the risk of false discovery enabling identification of biologically significant genome-wide methylation status using the HumanMethylation450 array,” *BMC Genomics*, vol. 15, no. 1, p. 51, 2014. DOI: [10.1186/1471-2164-15-51](https://doi.org/10.1186/1471-2164-15-51) [Online]. Available: <https://bmcbioinformatics.biomedcentral.com/articles/10.1186/1471-2164-15-51>

- [5] R. Pidsley, J. Y Wong, M. Volta, K. Lunnon, J. Mill, and L. C. Schalkwyk, “A data-driven approach to preprocessing illumina 450k methylation array data,” *Genome Biology*, vol. 17, no. 1, p. 84, 2016. DOI: [10.1186/s13059-016-1066-1](https://doi.org/10.1186/s13059-016-1066-1) [Online]. Available: <https://genomebiology.biomedcentral.com/articles/10.1186/s13059-016-1066-1>
- [6] C. S. Wilhelm-Benartzi, D. C. Koestler, M. R. Karagas, J. M. Flanagan, B. C. Christensen, J. K. Wiencke, K. T. Kelsey, C. J. Marsit, and A. E. Houseman, “Review of processing and analysis methods for dna methylation array data,” *British Journal of Cancer*, vol. 109, no. 6, pp. 1394–1402, 2013. DOI: [10.1038/bjc.2013.496](https://doi.org/10.1038/bjc.2013.496) [Online]. Available: <https://www.nature.com/articles/bjc2013496>
- [7] H. Naeem, N. C. Wong, Z. Chatterton, M. K. Hong, J. S. Pedersen, N. M. Corcoran, C. M. Hovens, and G. Macintyre, “Reducing the risk of false discovery enabling identification of biologically significant genome-wide methylation status using the humanmethylation450 array,” *BMC Genomics*, vol. 15, no. 514, 2014. DOI: [10.1186/1471-2164-15-514](https://doi.org/10.1186/1471-2164-15-514) [Online]. Available: <https://bmcbioinformatics.biomedcentral.com/articles/10.1186/1471-2164-15-514>
- [8] Y. A. Chen, M. Lemire, S. Choufani, D. T. Butcher, D. Grafodatskaya, B. W. Zanke, S. Gallinger, T. J. Hudson, and R. Weksberg, “Discovery of cross-reactive probes and polymorphic cpgs in the illumina infinium humanmethylation450 microarray,” *Epigenetics*, vol. 8, no. 2, pp. 203–209, 2013. DOI: [10.4161/epi.23470](https://doi.org/10.4161/epi.23470) [Online]. Available: <https://www.tandfonline.com/doi/full/10.4161/epi.23470>
- [9] R. Pidsley, E. Zotenko, T. J. Peters, M. G. Lawrence, G. P. Risbridger, P. Molloy, S. Van Djik, B. Muhlhausler, C. Stirzaker, and S. J. Clark, “Critical evaluation of the illumina methylationepic beadchip microarray for whole-genome dna methylation profiling,” *Genome Biology*, vol. 17, no. 1, p. 208, 2016. DOI: [10.1186/s13059-016-1066-1](https://doi.org/10.1186/s13059-016-1066-1) [Online]. Available: <https://genomebiology.biomedcentral.com/articles/10.1186/s13059-016-1066-1>
- [10] W. Zhou, P. W. Laird, and H. Shen, “Comprehensive characterization, annotation and innovative use of infinium dna methylation beadchip probes,” *Epigenetics & Chromatin*, vol. 9, no. 37, 2016. DOI: [10.1186/s13072-016-0084-1](https://doi.org/10.1186/s13072-016-0084-1) [Online]. Available: <https://academic.oup.com/nar/article/45/4/e22/2290930>
- [11] D. L. McCartney, R. M. Walker, S. W. Morris, A. M. McIntosh, D. J. Porteous, and K. L. Evans, “Identification of polymorphic and off-target probe binding sites on the illumina infinium methylationepic beadchip,” *Epigenetics*, vol. 11, no. 2, pp. 118–128, 2016. DOI: [10.1080/15592294.2016.1146858](https://doi.org/10.1080/15592294.2016.1146858) [Online]. Available: <https://www.sciencedirect.com/science/article/pii/S221359601630071X>